Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Lactate, Sodium
1. Compound Sodium Lactate Solution
2. 72-17-3
3. Sodium Dl-lactate
4. Lactic Acid Sodium Salt
5. Monosodium Lactate
6. Sodium 2-hydroxypropanoate
7. Lacolin
8. Per-glycerin
9. Lactic Acid, Monosodium Salt
10. Sodium Alpha-hydroxypropionate
11. Monosodium 2-hydroxypropanoate
12. Propanoic Acid, 2-hydroxy-, Monosodium Salt
13. 312-85-6
14. Sodium (dl)-lactate
15. Ccris 7316
16. Natrum Lacticum
17. 2-hydroxypropanoic Acid, Monosodium Salt
18. Compound Solution Of Sodium Lactate
19. Dl-lactic Acid Sodium Salt
20. Lactate (sodium)
21. E325
22. Ai3-03131
23. Sodium Lactate Solution
24. Tu7hw0w0qt
25. Sodium (lactate) Anhydrous
26. Ins No.325
27. (+/-)-2-hydroxypropionic Acid Sodium Salt
28. Chebi:75228
29. Ins-325
30. (2r)-2-hydroxypropanoate (sodium)
31. Nsc-31718
32. Compound Solution Of Sodium Lactate [inn]
33. Dl-lactic Acid Sodium Salt, 60% W/w Syrup
34. E-325
35. Chembl1357
36. Lactic Acid, Sodium Salt (van)
37. Einecs 200-772-0
38. Einecs 206-231-5
39. Unii-tu7hw0w0qt
40. Nsc 31718
41. Sodium 2-hydroxypropionate
42. Sodium Lactate [usp:jan]
43. Mediject L
44. Sodiumdl-lactate
45. Sodium Lactate In Plastic Container
46. Mediject L (tn)
47. Mfcd00065400
48. Purasal S/sp 60
49. Sodium Lactate (7ci)
50. Sodium2-hydroxypropanoate
51. Sodium;2-hydroxypropanoate
52. Sodium Dl-lactate Solution
53. Ec 200-772-0
54. Sodium Lactate 1/6 Molar In Plastic Container
55. Schembl4360
56. Sodium Lactate (jan/usp)
57. Sodium Lactate [ii]
58. Sodium Lactate [mi]
59. Sodium Lactate 0.167 Molar In Plastic Container
60. Sodium Lactate [jan]
61. Sodium Lactate [inci]
62. Natrum Lacticum [hpus]
63. Sodium Lactate [vandf]
64. Dtxsid6052829
65. Sodium Lactate [usp-rs]
66. Sodium Lactate [who-dd]
67. Hy-b2227b
68. Pharmakon1600-01300036
69. 2-hydroxypropionic Acid Sodium Salt
70. Sodium Lactate, (+/-)-
71. Lactic Acid, Monosodium Salt (8ci)
72. Nsc760108
73. Sodium Lactate [orange Book]
74. Sodium Lactate [usp Impurity]
75. Sodium Lactate Solution [fcc]
76. Akos015915154
77. Lacolin And Dl-lactic Acid Sodium Salt
78. Nsc-760108
79. Sb44210
80. Db-079226
81. Cs-0030973
82. E 325
83. Ft-0656540
84. Ft-0689056
85. Ft-0771022
86. S0928
87. Sodium Dl-lactate, 60% W/w Aqueous Solution
88. Sodium Lactate Solution [ep Monograph]
89. D02183
90. H11285
91. Propanoic Acid, 2-hydroxy-, Sodium Salt (1:1)
92. Q418235
93. Propanoic Acid, 2-hydroxy-, Monosodium Salt (9ci)
94. W-104498
| Molecular Weight | 112.06 g/mol |
|---|---|
| Molecular Formula | C3H5NaO3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 112.01363830 g/mol |
| Monoisotopic Mass | 112.01363830 g/mol |
| Topological Polar Surface Area | 60.4 Ų |
| Heavy Atom Count | 7 |
| Formal Charge | 0 |
| Complexity | 63.2 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.
Lead Product(s): Sodium Lactate,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Instituto de Salud Carlos III | Universidad Miguel Hernandez de Elche | Hospital del Mar | Hospital Clinico Universitario de Santiago | Hospital Clínico Universitario de Valencia | Hospital Costa del Sol | Corporacion Parc Tauli | Hospital Clínico Univers
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2023

Lead Product(s) : Sodium Lactate,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Instituto de Salud Carlos III | Universidad Miguel Hernandez de Elche | Hospital del Mar | Hospital Clinico Universitario de Santiago | Hospital Clínico Universitario de Valencia | Hospital Costa del Sol | Corporacion Parc Tauli | Hospital Clínico Univers
Deal Size : Inapplicable
Deal Type : Inapplicable
Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Albumin is a Other Large Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Albumin,Sodium Lactate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: GC Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Albumin,Sodium Lactate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : GC Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Ascites Replacement Strategy on Time to 1st Flatus After LDLT
Details : Albumin is a Other Large Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 03, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.
Lead Product(s): Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2019

Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Shock.
Lead Product(s): Sodium Lactate,Plasma-Lyte
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Boston Children's Hospital | Children's Healthcare of Atlanta | Children's Hospital Colorado | Children's Hospital Los Angeles | The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | Children's Hospital and Health System F
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2019

Lead Product(s) : Sodium Lactate,Plasma-Lyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Boston Children's Hospital | Children's Healthcare of Atlanta | Children's Hospital Colorado | Children's Hospital Los Angeles | The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | Children's Hospital and Health System F
Deal Size : Inapplicable
Deal Type : Inapplicable
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Shock.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pneumonia.
Lead Product(s): Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pneumonia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Peritonitis.
Lead Product(s): Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritoniti...
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Peritonitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sepsis.
Lead Product(s): Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Lactate,Sorbitol,Sodium Chloride,Calcium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2018

Details:
Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.
Lead Product(s): Sodium Lactate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Innogene Kalbiotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 11, 2013

Lead Product(s) : Sodium Lactate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Innogene Kalbiotech
Deal Size : Inapplicable
Deal Type : Inapplicable
0.5M Na Lactate Solution in Acute Heart Failure (AHF)
Details : Sodium Lactate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2013

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
99
PharmaCompass offers a list of Sodium Lactate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Lactate manufacturer or Sodium Lactate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Lactate manufacturer or Sodium Lactate supplier.
PharmaCompass also assists you with knowing the Sodium Lactate API Price utilized in the formulation of products. Sodium Lactate API Price is not always fixed or binding as the Sodium Lactate Price is obtained through a variety of data sources. The Sodium Lactate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4, including repackagers and relabelers. The FDA regulates DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 supplier is an individual or a company that provides DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 active pharmaceutical ingredient (API) or DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 finished formulations upon request. The DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers may include DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 API manufacturers, exporters, distributors and traders.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 DMF (Drug Master File) is a document detailing the whole manufacturing process of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 active pharmaceutical ingredient (API) in detail. Different forms of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 DMFs exist exist since differing nations have different regulations, such as DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 DMF submitted to regulatory agencies in the US is known as a USDMF. DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 USDMF includes data on DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 Drug Master File in Japan (DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 JDMF) empowers DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 JDMF during the approval evaluation for pharmaceutical products. At the time of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers with JDMF on PharmaCompass.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP of the European Pharmacopoeia monograph is often referred to as a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 Certificate of Suitability (COS). The purpose of a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 to their clients by showing that a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP has been issued for it. The manufacturer submits a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP holder for the record. Additionally, the data presented in the DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 DMF.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 suppliers with NDC on PharmaCompass.
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 GMP manufacturer or DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 GMP API supplier for your needs.
A DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CoA (Certificate of Analysis) is a formal document that attests to DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4's compliance with DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 specifications and serves as a tool for batch-level quality control.
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CoA mostly includes findings from lab analyses of a specific batch. For each DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 may be tested according to a variety of international standards, such as European Pharmacopoeia (DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 EP), DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER-4 USP).